MIM
AVIR icon

MetLife Investment Management’s Atea Pharmaceuticals AVIR Stock Holding History

MetLife Investment Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$184K Sell
39,466
-312
-0.8% -$1.55K ﹤0.01% 2462
2026
Q1 		$214K Buy
39,778
+10,060
+34% +$46.2K ﹤0.01% 2188
2025
Q4 		$106K Sell
29,718
-16,227
-35% -$51.6K ﹤0.01% 2576
2025
Q3 		$133K Buy
45,945
+420
+0.9% +$1.43K ﹤0.01% 2522
2025
Q2 		$164K Buy
45,525
+69
+0.2% +$206 ﹤0.01% 2287
2025
Q1 		$136K Buy
45,456
+8,365
+23% +$26.1K ﹤0.01% 2385
2024
Q4 		$124K Sell
37,091
-8,109
-18% -$26.9K ﹤0.01% 2524
2024
Q3 		$151K Hold
45,200
– – ﹤0.01% 2433
2024
Q2 		$150K Buy
45,200
+7,475
+20% +$27.9K ﹤0.01% 2413
2024
Q1 		$152K Sell
37,725
-9,509
-20% -$37.2K ﹤0.01% 2336
2023
Q4 		$144K Hold
47,234
– – ﹤0.01% 2415
2023
Q3 		$142K Hold
47,234
– – ﹤0.01% 2398
2023
Q2 		$177K Hold
47,234
– – ﹤0.01% 2354
2023
Q1 		$158K Hold
47,234
– – ﹤0.01% 2357
2022
Q4 		$227K Hold
47,234
– – ﹤0.01% 2172
2022
Q3 		$269K Buy
47,234
+8,168
+21% +$62.5K ﹤0.01% 2099
2022
Q2 		$277K Hold
39,066
– – ﹤0.01% 2074
2022
Q1 		$282K Buy
39,066
+14,418
+58% +$97.9K ﹤0.01% 2128
2021
Q4 		$220K Hold
24,648
– – ﹤0.01% 1992
2021
Q3 		$864K Hold
24,648
– – 0.01% 1196
2021
Q2 		$529K Buy
24,648
+19,099
+344% +$574K ﹤0.01% 1537
2021
Q1 		$343K Sell
5,549
-1,387
-20% -$93.7K ﹤0.01% 1740
2020
Q4 		$290K Buy
+6,936
New +$224K ﹤0.01% 1785

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MetLife Investment Management's AVIR Position: Q2 2026 in Review

MetLife Investment Management reduced its Atea Pharmaceuticals (AVIR) stake by 0.78% in Q2 2026, selling an estimated $1.55K and leaving 39,466 shares worth $184K. The position accounts for ﹤0.01% of the portfolio, ranked #2462.

MetLife Investment Management first reported a position in AVIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $864K in Q3 2021. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • MetLife Investment Management held 39,466 shares of Atea Pharmaceuticals worth $184K as of Q2 2026.
  • MetLife Investment Management sold 312 Atea Pharmaceuticals shares in Q2 2026, an estimated $1.55K.
  • Atea Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2462 holding.
  • MetLife Investment Management first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • MetLife Investment Management's Atea Pharmaceuticals position peaked at $864K in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.